Plain-English translation of NCT07098364 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called ST-067 given together with liso-cel, an established immune cell therapy, for patients with advanced B-cell lymphoma that has returned or no longer responds to standard treatments. The study involves about 33 patients and will measure whether this combination is safe and how well it works. This is the first time researchers are studying ST-067 in this combination, so they will start with smaller doses and gradually increase them to find the right amount.
Many patients with aggressive lymphoma stop responding to standard chemotherapy or see their cancer come back after treatment. While liso-cel therapy has shown promise, researchers want to know if adding this medication could make it work even better or help more patients benefit from the treatment.
You likely qualify if…
You likely don't qualify if…
You will first have a procedure called leukapheresis to collect some of your immune cells, followed by chemotherapy to prepare your body for treatment. On day 0, you'll receive liso-cel as an intravenous infusion. Two weeks later, you'll begin weekly injections of ST-067 under the skin for up to 8 doses over about two months. Throughout the study, you'll have blood tests, imaging scans, and heart and lung function tests. After treatment ends, you'll have follow-up visits at 3, 6, 9, and 12 months, then continue with long-term monitoring as part of standard care.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States